Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17000023 | 0.77 | CYP3A4 (0.43) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL16999891 | 0.75 | CYP3A4 (0.45) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL16999935 | 0.74 | CYP3A4 (0.44) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL10800827 | 0.74 | HMGCR (0.46) | HMGCRCYP3A4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL16999946 | 0.72 | PPARD (0.40) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL19193115 | 0.72 | CYP3A4 (0.44) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17000022 | 0.70 | CYP3A4 (0.44) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL16999890 | 0.70 | CYP3A4 (0.39) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL16999932 | 0.69 | PTGS1 (0.45) | CYP3A4SMN1; SMN2NPC1PKMHTT | |
| SCHEMBL16999944 | 0.69 | ESR1 (0.41) | CYP3A4SMN1; SMN2NPC1PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | Kazia Therapeutics Limited (AU) | 2019-08-06 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| EP-2953938-B1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Novogen ltd (AU) | 2017-08-02 | — | — | EP | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| WO-2015117202-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | NOVOGEN LIMITED (AU) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, BRAP, EP300 | HMGCR 4129/4885CYP3A4 145/4885SMN1; SMN2 26/4885 |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, VHL, NQO1 | HMGCR 1943/4885CYP3A4 57/4885SMN1; SMN2 2972/4885 |
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | BRCA1, BRAP, EP300 | HMGCR 4129/4885CYP3A4 145/4885SMN1; SMN2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.